Institutional Biosafety Committee (IBC)
The ISMMS Institutional Biosafety Program monitors all laboratory activities involving recombinant DNA and synthetic DNA molecules as required by the National Institute of Health (NIH) Guidelines. They also oversee research involving biological agents and biological toxins. As mandated by the guidelines, the Institutional Biosafety Committee (IBC) must review and approve any research involving the use of the following hazardous materials regardless of the funding source:
- Recombinant and synthetic nucleic acids
- Infectious agents
- Select agents & toxins, as per the Federal Select Agent Program
- Human materials (including all fluids, tissues, excretions, secretions, cell lines) utilizing infectious agents and/or recombinant/synthetic nucleic acids
- Nonhuman primate materials (including live animals, all fluids, tissues, excretions, secretions, cell lines) utilizing infectious agents and/or recombinant/synthetic nucleic acids
- Genetically modified animals and whole plants
- Certain animals or specimens know to be reservoirs/vectors of zoonotic disease
Approval is required before starting work. The PI is responsible for updating the IBC protocol (s) to include modifications to personnel, locations, materials, procedures, etc.
Principal Investigators are required to complete and submit applications in eSafety three full weeks before the IBC meetings dates. The IBC application should be submitted in parallel with the IACUC submission, if applicable.
Every 3 Years
Contact the Institutional Biosafety Committee (IBC) at email@example.com or (212) 241-0704.
Last Updated: July 2023
Research 411 Portal
Still Need Help?